AM Chemicals

Name

AM Chemicals

Legal name

AM Chemicals LLC

Website

https://amchemicals.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

1–10 employees

Short description

AM Chemicals LLC supplies patented solid supports, phosphoramidites, and reagents for oligonucleotide synthesis, including Trident Universal Solid Supports, DDTT sulfurization reagent, and GalNAc modifiers, serving pharmaceutical, biotech, and diagnostics customers globally.

Ownership category

akta.pro rank

Product category

Specialty Chemicals / Oligonucleotide Synthesis Reagents

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731), Industrial Organic Chemicals (2860)

akta.pro primary industry

RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry) (HLAAADAE)

akta.pro secondary industries

RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF), RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD), mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF)

Keywords

• Oligonucleotide synthesis reagents
• Universal solid supports
• Phosphoramidite reagents
• Sulfurization reagents
• Radiolabeled oligonucleotide synthesis

Headquarters

HQ city

Vista

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Oligonucleotide Synthesis Products: Sale of solid supports, phosphoramidites, and reagents for oligonucleotide synthesis. Products include Trident Universal Solid Supports, universal phosphoramidites, sugar-modified nucleoside phosphoramidites, and modifier phosphoramidites. Revenue from unit-based product sales with pricing tiers based on package size.
2. Custom Radiolabeled Oligonucleotide Synthesis Services: Expert synthesis of radiolabeled oligonucleotides (14C, 35S, and 3H) and phosphorothioate analogs. Services include synthesis of radiolabeled phosphoramidite building blocks, oligo synthesis, deprotection, purification, HPLC, desalting, duplex formation, and optional GMP conditions. Lead time 8-12 weeks.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

AM Chemicals manufactures and supplies proprietary solid supports, phosphoramidites, and reagents used by researchers and pharmaceutical manufacturers to synthesize DNA and RNA oligonucleotides. Its flagship Trident line offers universal solid supports that eliminate the need for nucleosidic supports, complemented by DDTT sulfurization reagent, sugar-modified nucleoside phosphoramidites, non-nucleosidic modifier phosphoramidites (for functional groups and cellular uptake), and custom radiolabeled oligonucleotide synthesis services (14C, 35S, 3H).

Product overview

AM Chemicals offers a comprehensive portfolio of products for oligonucleotide synthesis, established in 2003. The core product line centers on the Trident Universal Solid Supports, which represent a novel universal support system eliminating the need for nucleosidic solid supports. The product range includes Unprotected and DMT-protected Universal Solid Supports, Universal Phosphoramidite, and Sugar-modified Nucleoside Phosphoramidites (Glucose, Galactose, GlcNAc, GalNAc variants). Supporting these are Non-nucleosidic Modifier products for introducing functional groups (TFA Amino, Alkyne, Fluorescein, Biotin, Pyrene, Dabsyl, Dabcyl) and cellular uptake modifiers (GalNAc, Cholesteryl, DL-tocopherol, Palmitoyl, Linoleic, Linolenic). The DDTT Sulfurization Reagent provides efficient sulfur transfer for phosphorothioate synthesis. The company also offers Custom Radiolabeled Oligonucleotide Synthesis services using 14C, 35S, and 3H isotopes. Distribution is handled through Glen Research as a key distribution partner.

Differentiator

Problem solved

Functional benefit

Brands

• Trident: Trident Universal Solid Supports - a novel universal support product line for oligonucleotide synthesis.

Products and services

• Trident Universal Solid Supports Proprietary universal solid supports that allow synthesis of oligonucleotides starting from a single support regardless of the 3'-terminal nucleoside, eliminating the need for nucleosidic solid supports. Available in CPG (500, 1000, 1400, 2000, 3000 Angstrom) and Polystyrene variants. Targeted at oligonucleotide synthesis researchers and manufacturers.
• DDTT Sulfurization Reagent Efficient sulfur transfer reagent for preparation of DNA and RNA phosphorothioates with extremely high yields and excellent solution stability (over 6 months). For oligonucleotide synthesis labs requiring phosphorothioate backbone modifications.
• Universal Phosphoramidite Non-nucleosidic phosphoramidite that eliminates the need for nucleosidic solid supports, enabling synthesis of most oligonucleotides from a single OH- or NH2-functionalized solid support regardless of desired 3'-terminal nucleoside.
• Sugar-modified Nucleoside Phosphoramidites Sugar-modified phosphoramidites including Glucose, Galactose, GlcNAc, and GalNAc variants with DMT-protected nucleosides (dA, dC, dG, dT) and 2'-OMe modifications for use in oligonucleotide synthesis.
• Non-nucleosidic Modifier Phosphoramidites for Functional Groups Non-nucleosidic phosphoramidites for introducing functional and reporter groups including TFA Amino, Alkyne, Fluorescein, Biotin, Pyrene, Dabsyl, and Dabcyl at any desired position of oligonucleotides. For labeling applications.
• Non-nucleosidic Modifier Phosphoramidites for Cellular Uptake Non-nucleosidic phosphoramidites for targeted cellular uptake including GalNAc, Cholesteryl, DL-tocopherol, Palmitoyl, Linoleic, and Linolenic for efficient cellular uptake of oligonucleotides.
• Custom Radiolabeled Oligonucleotide Synthesis Service Expert synthesis of radiolabeled oligonucleotides using 14C, 35S, and 3H isotopes and their phosphorothioate analogs. Includes synthesis of radiolabeled protected nucleoside phosphoramidite reagents, oligo synthesis, deprotection, purification, desalting, and optional GMP conditions. Lead time 8-12 weeks.
• Unprotected Universal Solid Supports Universal solid supports with unprotected linkers (CAS #: 3031397-94-8) for oligonucleotide synthesis workflows that do not require DMT protection.
• DMT-protected Universal Solid Supports DMT-protected universal solid supports for oligonucleotide synthesis workflows requiring DMT protection during synthesis cycles.

Quantifiable outcome

• >90% yield of full-PS 20-mer RNA achieved with DDTT using 0.05M solution and 4 min contact time
• +3 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Aligos TherapeuticscoreOEM/ Whitelabel/ Licensing Partner · 5 March 2024AM Chemicals LLC entered into a license and supply agreement with Aligos Therapeutics whereby an exclusive license for the right to the use of specific GalNAc phosphoramidites for oligonucleotide therapeutic applications has been granted.
• Olix PharmaceuticalscoreOEM/ Whitelabel/ Licensing Partner · 5 March 2024AM Chemicals LLC entered into a license and supply agreement with Olix Pharmaceuticals whereby an exclusive license for the right to the use of selected GalNAc-modified phosphoramidites and solid supports for liver targeting strategies has been granted. An oligonucleotide compound (OLX75016) containing a GalNAc linker licensed from AM Chemicals is currently in Phase 1 clinical trials.
• Glen ResearchcoreChannel Partner/ Reseller/ DistributorAM Chemicals LLC entered into an agreement with Glen Research whereby a license to commercialize (for research purposes only) selected GalNAc phosphoramidites and GalNAc solid supports for oligonucleotide synthesis and applications has been granted. Glen Research also distributes DDTT and GalNAc products in small quantities.
• ChemGenesminorOEM/ Whitelabel/ Licensing PartnerAM Chemicals LLC entered into an agreement with ChemGenes whereby a license to commercialize selected reagents for oligonucleotide synthesis has been granted.
• GeneLinkminorOEM/ Whitelabel/ Licensing PartnerAM Chemicals LLC entered into a license agreement with GeneLink whereby a non-exclusive license for the right to manufacture, market and sell oligonucleotide conjugates using selected GalNAc-modified phosphoramidites and solid supports has been granted.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• LGC Group: LGC owns Biosearch Technologies and other life science tools brands with overlapping phosphoramidite and oligo synthesis reagent offerings. A broad incumbent that could acquire or partner with specialty players like AM Chemicals to expand its oligo chemistry footprint.
• Merck (Sigma-Aldrich): Merck's life science segment supplies a broad catalog of phosphoramidites, solid supports, and oligonucleotide synthesis reagents through the Sigma-Aldrich brand. A broad incumbent with overlapping product lines across all major oligo chemistry categories and global distribution scale.
• Biosearch Technologies: Biosearch Technologies (now part of LGC) develops oligonucleotide synthesis reagents, fluorescent probes, and qPCR/NGS consumables. A broader incumbent offering overlapping phosphoramidite and probe chemistry with deeper resources and global reach.
• Thermo Fisher Scientific: Thermo Fisher offers oligonucleotide synthesis reagents, custom oligo services, and CDMO capabilities through multiple brands (e.g., Thermo Scientific chemicals). A broad incumbent with the scale to vertically integrate around competing chemistries or acquire specialty players like AM Chemicals.
• Integrated DNA Technologies (IDT): IDT (now part of Danaher) is the largest custom oligonucleotide synthesis provider, offering both standard and modified oligos, reagents, and probes at industrial scale. A broad incumbent with overlapping oligo synthesis chemistry capability and far larger commercial reach.

Emerging players

• Asymchem: Asymchem has built oligonucleotide CDMO capabilities alongside its broader small molecule API and peptide services, targeting therapeutic oligo customers. Increasingly competitive in custom oligo synthesis services that overlap with AM Chemicals' service offering.

Direct peers

• ChemGenes: ChemGenes is an oligonucleotide synthesis reagent supplier and license partner of AM Chemicals. Sells phosphoramidites, solid supports, and ancillary reagents to the same pharma, biotech, and CDMO customer base, including custom synthesis services.
• Eurogentec: Eurogentec provides custom oligonucleotide synthesis services and reagents, including modified oligos for therapeutic and diagnostic use. Overlapping specialty reagent and CDMO service offerings with AM Chemicals' custom radiolabeled oligo synthesis business.
• Nitto Denko Avecia: Avecia is a leading oligonucleotide CDMO offering development and GMP manufacturing services for therapeutic oligos, including antisense and siRNA. Overlaps with AM Chemicals' custom synthesis service line and is a downstream buyer of oligonucleotide reagents and solid supports.
• Glen Research: Glen Research is both a competitor (manufactures phosphoramidites, solid supports, and ancillary reagents for oligonucleotide synthesis) and a distribution partner for AM Chemicals' DDTT and GalNAc products in small quantities. Directly overlapping product portfolio targeting the same research and CDMO customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/am-chemicals-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AM Chemicals